Diffusion Basis Spectrum Imaging of the Prostate

Recruiting now · Not applicable

Conditions studied: Prostate Cancer

In brief

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

Key facts

Study ID: NCT04420702
Run by: Washington University School of Medicine
People needed: 500
Starts: 2020-02-27
Expected to finish: 2027-05-31
Last updated by the study team: 2026-07-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Over 18 years of age and willing and able to provide informed consent.
Patients with no prior diagnosis of prostate cancer, who are planning to undergo prostate biopsy as clinical standard of care ("early detection cohort")
Including those men with:
an elevated PSA and no prior biopsy
an elevated PSA and a negative prior biopsy
Patients with a prior diagnosis of prostate cancer, who are currently managed with active surveillance, who are planning to undergo biopsy as clinical standard of care ("active surveillance cohort")

You may not qualify if…

Patients with any clinical contraindication to MRI
Including but not limited to:
Those with metallic implants, such as pacemakers or implantable cardioverter-defibrillators
Those with cochlear implants
Those with claustrophobia not relieved with medications (patients with claustrophobia who do not need medications for the scan or whose claustrophobia can be managed with medication, are eligible to participate)
Those who cannot lie flat for over 1 hour
Patients with prior prostate surgery for prostate cancer (e.g. radical prostatectomy, focal ablation)

Where it is running

Washington University School of Medicine — St Louis, Missouri, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.